证券代码：688658 证券简称：悦康药业 公告编号：2023-046 悦康药业集团股份有限公司 关于自愿披露注射用头孢哌酮钠舒巴坦钠 通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 注册分类：化学药品 原药品批准文号：国药准字 H20043010 近日，悦康药业集团股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的关于注射用头孢哌酮钠舒巴坦钠（规格：1.0g）的《药品补充 申请批准通知书》（通知书编号：2023B03575），该药品通过仿制药质量和疗效一 致性评价。 一、上述药品的基本情况 药品名称：注射用头孢哌酮钠舒巴坦钠 剂型：注射剂 规格：1.0g（C₂₅H₂₇N₉0₈S₂ 0.5g 与 C₈H₁₁N0₅S 0.5g） 上市许可持有人：悦康药业集团股份有限公司 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医疗 器械审评审批制度的意见》（国发〔2015〕44 号）、《关于仿制药质量和疗效一致 性评价工作有关事项的公告》（2017 年第 100 号）和《国 ...

证券代码：688658 证券简称：悦康药业 公告编号：2023-045 悦康药业集团股份有限公司 关于变更保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 悦康药业集团股份有限公司（以下简称"公司"）于 2023 年 8 月 8 日收到中 信证券股份有限公司（以下简称"中信证券"）关于更换持续督导保荐代表人的 书面函。中信证券为公司首次公开发行股票并在科创板上市项目（以下简称"首 发上市项目"）的保荐人，原指定洪立斌先生、罗耸先生担任保荐代表人。现罗 耸先生因工作变动原因，不再担任公司持续督导保荐代表人。 附件：王天祺女士的简历 特此公告。 悦康药业集团股份有限公司董事会 2023 年 8 月 9 日 附件： 王天祺女士的简历 王天祺女士，保荐代表人，现任中信证券全球投资银行管理委员会副总裁。 先后负责或参与洁美科技非公开、洁美科技可转债、星源材质非公开、湘电股份 非公开、长源电力发行股份购买资产等项目。王天祺女士在保荐业务执业过程中 严格遵守《证券发行上市保荐业务管理办法》等相关规定，执业记录良好。 为保 ...

证券代码：688658 证券简称：悦康药业 公告编号：2023-031 （网址：https://roadshow.sseinfo.com/） 悦康药业集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 三、参加人员 董事长：于伟仕 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 6 月 12 日(星期一)至 6 月 16 日(星期五)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过悦康药业集团股份有限公司 （以下简称"公司"）邮箱（irm@youcareyk.com）进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 公司已于 2023 年 4 月 28 日发布公司 2022 年度报告、2023 年第一季度报 告。为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季度经营 成果、财务状况，公司计划于 2023 年 6 月 19 日上午 10:00-11:00 举 ...

Financial Performance - The proposed cash dividend for 2022 is RMB 11.00 per 10 shares, totaling RMB 494.5 million based on a total share capital of 450 million shares[6]. - The net profit attributable to shareholders for 2022 is RMB 335.0147 million, with a cash dividend payout ratio of 147.75%[6]. - The company's operating revenue for 2022 was CNY 4,541,945,402.40, a decrease of 8.53% compared to CNY 4,965,725,984.69 in 2021[23]. - The net profit attributable to shareholders for 2022 was CNY 335,014,720.83, down 38.57% from CNY 545,316,048.79 in 2021[23]. - The net cash flow from operating activities was negative CNY 121,168,954.78, a decline of 123.52% compared to CNY 515,238,540.75 in 2021[23]. - The basic earnings per share for 2022 were CNY 0.74, a decrease of 38.84% from CNY 1.21 in 2021[24]. - The total revenue for 2022 was 4,541,945,402.40 RMB, with a net profit of 373,529,813.99 RMB before accounting for share-based payments[33]. - The company reported a 31.30% year-on-year decrease in net profit after excluding the impact of share-based payments[32]. - The company achieved a total R&D investment of CNY 451.84 million in 2022, representing a 73.25% increase compared to the previous year[71]. Operational Risks and Governance - The company has detailed various operational risks and corresponding mitigation measures in the report[4]. - The company has received a standard unqualified audit report from the accounting firm Rongcheng[5]. - There are no significant non-operating fund occupations by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not faced any issues with a majority of directors being unable to ensure the authenticity and completeness of the annual report[8]. - The company has not reported any special arrangements for corporate governance[8]. - The report includes a forward-looking statement risk disclaimer, indicating that future plans and strategies do not constitute a commitment to investors[7]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 9.95% in 2022, up 4.70 percentage points from 5.25% in 2021[24]. - The company is focusing on the development of innovative drugs and improving existing formulations to enhance clinical advantages[16]. - The company has established 9 core R&D platforms and has a total of 54 ongoing R&D projects, including 16 innovative drugs and 38 generic drugs[38]. - The company has received a total of 205 patents, with 79 new patents applied for in 2022, including 48 invention patents[38]. - The company has a strong R&D focus in areas such as cardiovascular, digestive systems, diabetes, reproductive systems, oncology, and anticoagulation, with a rich pipeline of products[145]. - The company is currently conducting clinical trials for multiple projects, including YKYY009, which targets the Omicron variant of the coronavirus[75]. - The company has ongoing projects in the development of mRNA vaccines and nucleic acid drugs, with significant progress reported in clinical phases[75]. - The company has made significant advancements in peptide drug development, establishing a comprehensive research system that integrates drug discovery and clinical development[65]. Market and Competitive Position - The pharmaceutical manufacturing industry in China experienced a revenue decline of 1.6% in 2022, totaling CNY 2,911.14 billion, with a profit drop of 31.8% to CNY 428.87 billion[54]. - The company has been recognized among the top 100 pharmaceutical manufacturers in China, reflecting its strong market position and operational capabilities[56]. - The company is recognized as a leading entity in the nucleic acid and peptide drug development sectors, being one of the few firms with capabilities in mRNA vaccines, small nucleic acid drugs, and peptide drugs[57]. - The company has a diverse product portfolio covering cardiovascular, digestive, anti-infection, endocrine, oncology, and reproductive health medications[56]. - The company is committed to international expansion, increasing the proportion of overseas sales revenue, and enhancing production processes to meet international standards[156]. Financial Management and Investments - The company has a comprehensive quality management system in place, adhering to GMP standards, ensuring product safety and quality throughout the manufacturing process[47]. - The company has a robust process development and scale-up platform that meets international quality requirements for GMP production of candidate small nucleic acids and mRNA vaccines[65]. - The company has established a technology platform for high-end pharmaceutical excipients, producing unique products with significant performance and cost advantages[66]. - The company has received approval for new drug development projects, including a contraceptive drug with therapeutic effects, which was approved in April 2022[69]. - The company plans to continue expanding its mRNA nucleic acid drug platform, which has led to significant investment in R&D[106]. Human Resources and Management - The company has 537 R&D personnel, an increase from 347 in the previous period, representing 16.84% of the total workforce, up from 12.24%[79]. - The total pre-tax remuneration for the reporting period amounted to 1,321.46 million CNY[177]. - The company has a strong leadership team with extensive experience in the pharmaceutical industry, including roles in various associations and organizations[178]. - The company has established a talent development mechanism and is increasing the recruitment of outstanding talents to build an innovative and efficient team, ensuring human resource support for strategic goals[165]. - The company has implemented a comprehensive training plan to enhance employee skills and support business objectives[198]. Compliance and Regulatory Environment - The company has not faced any penalties from securities regulatory authorities in the past three years, indicating compliance with regulations[186]. - The company operates in a macroeconomic environment that is currently experiencing cyclical fluctuations, which could adversely affect its operating performance and profitability[101]. - The company is subject to risks from regulatory changes regarding key monitored drug lists, which could restrict sales of certain products[97]. - The company has established a compliance management system, but risks remain regarding improper commercial behavior by downstream clients or employees[92].

Financial Performance - Cash and cash equivalents decreased by 31.98% to CNY 1,656,970,499.09, primarily due to high cash outflows for long-term asset purchases and dividend payments [6]. - Accounts receivable increased by 50.32% to CNY 1,227,864,693.86, attributed to a decline in sales revenue and slower customer payment collection [6]. - The company reported a total sales expense of CNY 197,849.72 million, with a sales expense to operating income ratio of 43.56% [25]. - The company’s contract liabilities increased by 92.01% to CNY 57,088,712.19, reflecting an increase in advance payments for goods [6]. - The company’s other current assets rose by 119.96% to CNY 69,151,546.61, mainly due to an increase in prepaid income tax [6]. - The company’s deferred tax assets increased by 42.07% to CNY 17,538,993.20, attributed to higher inventory impairment provisions and deductible losses [6]. - The company plans to distribute cash dividends of RMB 6.80 per 10 shares, totaling RMB 306 million, which accounts for 56.11% of the net profit attributable to shareholders [117]. Research and Development - The company is preparing to submit a New Drug Application (NDA) for its innovative traditional Chinese medicine, Hydroxy Safflower Yellow A, after completing a Phase III clinical trial [15]. - The company plans to develop new antiviral peptide drugs YKYY018 and YKYY019 based on its peptide drug development platform technology [34]. - The company is focused on enhancing its nucleic acid drug platform technology, including the development of proprietary delivery systems and mRNA vaccine technologies [60]. - The company has developed a universal technology platform for small nucleic acid and mRNA drug development, contributing to the establishment of research pipelines for COVID-19 mRNA vaccines, rabies mRNA vaccines, and hepatitis B mRNA vaccines [69]. - The company has established a specialized peptide drug R&D team and platform, enhancing its capabilities in mRNA vaccines, small nucleic acid drugs, and peptide drugs [98]. - The company has ongoing projects in various innovative drug developments, including a new mRNA vaccine platform and clinical research on multiple drugs [77]. - The company has made significant progress in the development of its nucleic acid drug CT102, completing Phase I clinical trials on January 4, 2022, and initiating Phase IIa trials on March 24, 2022 [99]. - The company has received an important patent for a nucleic acid drug delivery system on April 15, 2022, which enhances the delivery efficiency of nucleic acid drugs [99]. - The company has applied for a total of 394 patents as of December 31, 2022, including 270 invention patents, with 205 patents granted [77]. - In 2022, the company increased its R&D investment by 73.25% to approximately CNY 451.84 million, representing 9.95% of total revenue, up from 5.25% in the previous year [81][82]. Corporate Governance and Shareholder Relations - The company emphasizes the importance of protecting the rights of minority shareholders and has held 2 shareholder meetings during the reporting period [65]. - The company has established a comprehensive communication channel with shareholders to ensure their rights are protected [65]. - The company has established a long-term mechanism for investor relations management to enhance communication regarding governance, development strategy, and operational status [177]. - The company’s management is focused on enhancing internal control systems and performance evaluation mechanisms for senior management [125]. - The company has implemented a restricted stock incentive plan in 2021, granting 13,000,000 shares, which accounts for 2.89% of the total shares [120]. Environmental and Social Responsibility - The company emphasizes ESG as a cornerstone for sustainable and long-term development, integrating it into corporate culture [153]. - The company has been recognized as a "National Green Factory" for its commitment to green development and environmental protection [154]. - The company reported actual emissions of chemical oxygen demand (COD) at 74.223 mg/L and ammonia nitrogen at 1.932 mg/L for its facilities, which are within permissible limits [158]. - The company invested 39.12 million yuan in environmental protection during the reporting period [178]. - The wastewater treatment system at Anhui Yuekang Kaiyue Pharmaceutical Co., Ltd. has a designed capacity of 50 tons per day and has been operating normally since its commissioning in 2018 [166]. - The company has not identified any significant internal control deficiencies during the reporting period [150]. - The company has not implemented an employee stock ownership plan during the reporting period [148]. Market Position and Industry Trends - The company has a strong market position with core products such as Ginkgo biloba extract injection and Omeprazole enteric-coated capsules, which hold significant market shares in their respective therapeutic areas [97]. - The domestic raw material drug industry is transitioning from low-end to mid-high end, with a focus on scale and intensive development, driven by national policies [104]. - R&D spending in the pharmaceutical industry is expected to grow, with global R&D expenditure projected to reach $295.4 billion by 2025, and domestic spending expected to grow at a CAGR of 15.0% [105]. - The normalization of volume-based procurement is expected to shorten the lifecycle of generic drugs and reduce profit margins, necessitating a diverse product line and cost control [106]. - The pharmaceutical industry is facing pressures for transformation and upgrading due to regulatory changes and increased quality standards, leading to potential mergers and acquisitions among companies [130]. - The company is positioned to benefit from the growing demand in the pharmaceutical sector, which is expected to maintain a stable growth trajectory [130].

Financial Performance - The company's operating revenue for Q1 2023 was RMB 1,128,554,211.20, representing a year-on-year increase of 25.28%[3] - The net profit attributable to shareholders for Q1 2023 was RMB 85,267,722.97, reflecting a growth of 34.35% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 83,120,811.26, which is an increase of 45.79% year-on-year[3] - The total operating profit for Q1 2023 reached CNY 96,308,524.11, up from CNY 64,302,047.67 in the same period last year, reflecting a growth of 49.83%[34] - The net profit for Q1 2023 was CNY 85,532,999.31, an increase of 33.73% compared to CNY 63,971,233.59 in Q1 2022[34] - The company reported a total comprehensive income attributable to shareholders of the parent company of CNY 85,267,722.97, compared to CNY 63,467,735.64 in the previous year, marking a 34.36% increase[35] Earnings and Shares - The basic earnings per share for Q1 2023 was RMB 0.19, an increase of 35.71% year-on-year[22] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.19, up from CNY 0.14 in Q1 2022, representing a growth of 35.71%[35] - The number of common shareholders at the end of the reporting period was 12,994[8] - The top ten shareholders hold a significant portion of the company's shares, with the largest shareholder owning 5,400,000 shares[27] Cash Flow and Investments - The net cash flow from operating activities for Q1 2023 was RMB 217,240,051.53, with no applicable year-on-year comparison[3] - Cash flow from operating activities for Q1 2023 was CNY 217,240,051.53, a significant improvement from a negative cash flow of CNY -32,912,014.96 in Q1 2022[36] - The company generated CNY 1,245,924,747.38 in cash inflows from operating activities, compared to CNY 1,099,933,827.58 in the previous year, indicating a growth of 13.27%[36] - The cash outflow from investing activities in Q1 2023 was CNY 120,799,575.39, compared to CNY 174,648,539.72 in Q1 2022, showing a decrease of 30.77%[37] - The net cash flow from financing activities for Q1 2023 was CNY -4,941,579.45, an improvement from CNY -9,086,512.50 in Q1 2022[37] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to RMB 6,274,070,620.90, a 4.42% increase from the end of the previous year[22] - Current liabilities rose to CNY 2,075,463,910.81, compared to CNY 1,899,350,053.82, reflecting an increase of about 9.29%[43] - Total liabilities reached CNY 2,182,169,374.02, an increase from CNY 2,011,390,540.27, indicating a growth of approximately 8.50%[43] - The company's equity attributable to shareholders increased to CNY 4,083,294,565.44 from CNY 3,988,972,492.50, marking a rise of about 2.37%[43] - Total assets increased to CNY 6,274,070,620.90, up from CNY 6,008,455,853.38, representing a growth of approximately 4.43%[42] Research and Development - The total R&D investment for Q1 2023 was RMB 88,048,480.27, which decreased by 18.09% compared to the same period last year[22] - R&D investment accounted for 7.80% of operating revenue, down 4.13 percentage points year-on-year[22] - Research and development expenses for Q1 2023 amounted to CNY 73,728,143.73, slightly down from CNY 73,938,790.33 in Q1 2022[33] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[33] Other Financial Metrics - The total operating costs for Q1 2023 were CNY 1,026,297,006.75, compared to CNY 841,629,577.42 in Q1 2022, indicating an increase of about 22%[33] - Tax and additional charges for Q1 2023 were CNY 13,235,710.21, compared to CNY 9,500,921.39 in Q1 2022, showing an increase of about 39%[33] - The company recorded a foreign exchange gain of CNY 1,739,256.84 in Q1 2023, contrasting with a loss of CNY -246,411.32 in the same period last year[37] - The company has ongoing development expenditures amounting to CNY 203,971,423.01, up from CNY 194,082,152.08, indicating an increase of approximately 5.00%[42]

Revenue and Profit - Revenue for Q3 2022 reached ¥1,573,105,309.87, an increase of 29.60% year-over-year[8] - Net profit attributable to shareholders was ¥195,204,855.01, up 21.54% compared to the same period last year[8] - Total operating revenue for the first three quarters of 2022 reached ¥3,502,028,882.01, an increase of 4.68% compared to ¥3,345,210,497.61 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was ¥337,783,347.02, a decrease of 9.27% from ¥372,438,690.81 in the same period last year[21] - The company reported a profit before tax of ¥382,616,542.36, down from ¥423,859,470.54 in the previous year, indicating a decline of 9.73%[21] Research and Development - R&D expenses totaled ¥109,084,572.55, representing a significant increase of 146.41% year-over-year[9] - The proportion of R&D expenses to revenue was 6.93%, an increase of 3.28 percentage points from the previous year[9] - Research and development expenses surged to ¥261,847,416.32, a significant increase of 164.5% compared to ¥98,871,475.74 in 2021[21] - The company plans to continue investing in R&D to enhance product offerings and market competitiveness[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,036,344,691.43, a 5.41% increase from the end of the previous year[9] - The total equity attributable to shareholders was ¥4,016,696,168.86, a 2.37% increase from the previous year[9] - Total liabilities increased to ¥2,012,250,438.07, compared to ¥1,799,673,767.06 in the previous year, reflecting a growth of 11.79%[20] - Current liabilities totaled approximately CNY 1.89 billion, up from CNY 1.68 billion, reflecting an increase of about 12.4%[19] - The total non-current assets reached approximately CNY 1.97 billion, an increase from CNY 1.66 billion, representing a growth of about 18.5%[19] Cash Flow - The company reported a net cash flow from operating activities of -¥17,933,153.46 for the year-to-date period[9] - The net cash flow from operating activities was -17,933,153.46, a significant decrease compared to 284,815,436.92 from the previous period[23] - Total cash inflow from operating activities was 3,315,838,808.93, while cash outflow was 3,333,771,962.39, resulting in a net cash flow of -17,933,153.46[23] - Cash inflow from investment activities was 63,890.00, with cash outflow totaling 514,029,681.38, leading to a net cash flow of -513,965,791.38[23] - Cash inflow from financing activities was 110,000,000.00, while cash outflow was 326,604,892.99, resulting in a net cash flow of -216,604,892.99[24] Other Financial Metrics - Basic earnings per share for the period were ¥0.43, reflecting a 19.44% increase year-over-year[9] - Earnings per share (EPS) for the first three quarters of 2022 was ¥0.75, down from ¥0.83 in 2021[22] - The company confirmed a share-based payment expense of ¥55,840,200.00 during the reporting period, affecting profit margins significantly[9] - The company received 15,487,034.63 in tax refunds, an increase from 4,631,448.62 in the previous period[23] - The company paid 306,538,734.72 in dividends and interest, compared to 204,621,081.43 in the previous period[24] Changes in Financial Position - The company's cash and cash equivalents decreased to approximately CNY 1.73 billion from CNY 2.44 billion, representing a decline of about 29%[18] - Accounts receivable increased significantly to approximately CNY 1.25 billion, up from CNY 816.81 million, marking an increase of approximately 53%[18] - Inventory levels rose to approximately CNY 746.55 million, compared to CNY 632.31 million, indicating an increase of about 18%[18] - The company reported a significant increase in employee compensation payments, totaling 330,632,595.38 compared to 244,752,646.11 previously[23] - The impact of exchange rate changes on cash and cash equivalents was 4,851,237.71, contrasting with -40,873.13 in the previous period[24] Corporate Developments - The company has not reported any significant new product launches or technological advancements during the reporting period[17] - There are no significant mergers or acquisitions reported in the current financial period[17]

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2022, representing a year-on-year increase of 15%[1] - Net profit attributable to shareholders reached 80 million CNY, up 20% compared to the same period last year[1] - The company's revenue for the first half of 2022 was CNY 1,928,923,572.14, a decrease of 9.50% compared to CNY 2,131,403,701.86 in the same period last year[26] - Net profit attributable to shareholders decreased by 34.11% to CNY 140,299,448.28 from CNY 212,940,271.97 year-on-year[26] - The net profit after deducting non-recurring gains and losses fell by 41.02% to CNY 123,400,490.87 compared to CNY 209,240,793.27 in the previous year[26] - The net cash flow from operating activities decreased by 175.59%, resulting in a negative cash flow of CNY -127,755,548.87[26] - Basic earnings per share decreased by 34.04% to CNY 0.31 from CNY 0.47 in the same period last year[26] - The company's operating revenue for the current period is ¥1,928,923,572.14, a decrease of 9.50% compared to the same period last year[143] - The company's operating costs decreased by 9.14% to ¥607,007,173.33, attributed to the impact of the pandemic[144] Research and Development - Research and development expenses increased by 25% to 50 million CNY, reflecting the company's commitment to innovation[1] - Research and development expenses accounted for 11.61% of revenue, an increase of 6.52 percentage points compared to 5.09% in the previous year[26] - The company reported a 37.10% year-on-year increase in R&D spending, reaching 11.534 billion yuan in 2021, with an estimated R&D expenditure of 6.978 billion yuan in the first half of 2021[70] - The company significantly increased R&D investment to CNY 224.04 million, representing a growth of 106.71% year-on-year, to enhance its innovation capabilities[117] - The company has 55 ongoing R&D projects, including 16 innovative drug projects and 39 generic drug projects, with a total of 178 patents obtained as of the report date[119] - The company has established nine core technology platforms, enhancing its innovation capabilities in drug development[110] - The company has developed a universal technology platform for small nucleic acid and mRNA drug development, aiding in the discovery of new targets and the design of nucleic acid sequences for various vaccines and therapeutics[85] - The company has achieved significant advancements in high-throughput screening technology, enabling efficient drug discovery for small nucleic acids and mRNA candidates[85] - The company has established a comprehensive quality control platform for nucleic acid drug development, ensuring product quality through modern analytical techniques[85] Market Expansion and Strategy - The company has expanded its user base by 10% in the first half of 2022, reaching a total of 1.2 million active users[1] - The company plans to launch three new products in the second half of 2022, focusing on innovative drug formulations[1] - The company is exploring potential mergers and acquisitions to enhance its market position and expand its product portfolio[1] - The management has provided a revenue guidance of 1.1 billion CNY for the full year 2022, indicating a growth target of 10%[1] - The company has successfully entered two new regional markets, increasing its geographical footprint[1] - The company is focusing on market expansion and optimizing revenue structure to mitigate the impact of the pandemic on sales[121] Risks and Challenges - The company has identified key risks including regulatory changes and market competition, with strategies in place to mitigate these risks[1] - The company attributed the decline in profits primarily to significant share-based payment expenses and increased R&D investments compared to the previous year[27] - The company faces risks related to new drug development, market promotion, and potential core technology leakage, which could impact its competitive advantage[126][127] - The company faced risks related to the rising prices of raw materials, which could negatively impact gross margins and net profits[130] - The implementation of centralized drug procurement policies poses a risk to the company's product pricing and profitability[135] Environmental Compliance - The company has been recognized as a key pollutant discharge unit in Beijing, with no environmental pollution incidents or administrative penalties reported during the reporting period[186] - The company operates a wastewater automatic online monitoring system at its facilities to ensure compliance with discharge standards[184] - The company has committed to stricter emission limits as per the local environmental protection regulations, demonstrating its dedication to sustainability[192] - The company has implemented advanced pollution control technologies, including a biological treatment process and activated carbon adsorption systems, to manage emissions effectively[196] Product Development and Innovation - The company has shifted its R&D focus towards mRNA vaccines and small nucleic acid drugs, marking a significant transformation in its innovation strategy[37] - The company aims to strengthen its competitive advantage through differentiated drug development in key therapeutic areas such as cardiovascular diseases and oncology[37] - The company is actively pursuing new consistency evaluation and generic drug projects, with eight new applications submitted[88] - The company has developed a platform for peptide drug development, focusing on innovative therapies for diabetes and osteoporosis[85] - The company has completed the preclinical research for the nucleic acid drug "Flu Tai De" and is awaiting approval[91] Human Resources and Talent Management - The number of R&D personnel increased to 530, accounting for 17.49% of the total workforce, up from 11.91% in the previous year[109] - The average salary for R&D personnel rose to 79,326.60 RMB, compared to 67,640.08 RMB in the same period last year, indicating a focus on attracting and retaining talent[109] - The R&D team includes 45 PhD holders, representing 8.49% of the total R&D personnel, indicating a strong academic foundation[109] - The company is actively pursuing strategic collaborations with research institutions to enhance its R&D capabilities and stay abreast of technological advancements[111]

Financial Performance - The net profit attributable to shareholders for 2021 was RMB 545.32 million[6]. - The company's total revenue for 2021 was approximately ¥4.97 billion, representing a year-over-year increase of 14.45% compared to ¥4.34 billion in 2020[29]. - Net profit attributable to shareholders was approximately ¥545.32 million, reflecting a growth of 23.34% from ¥442.14 million in the previous year[29]. - The net profit after deducting non-recurring gains and losses increased by 30.17% to approximately ¥510.34 million, up from ¥392.05 million in 2020[29]. - The company's cash flow from operating activities decreased by 26.15% to approximately ¥515.24 million, down from ¥697.66 million in 2020[29]. - The company's net assets attributable to shareholders increased by 9.57% to approximately ¥3.92 billion at the end of 2021, compared to ¥3.58 billion at the end of 2020[29]. - The total assets of the company grew by 4.94% to approximately ¥5.73 billion at the end of 2021, up from ¥5.46 billion at the end of 2020[29]. - The basic earnings per share for 2021 was ¥1.21, a slight decrease of 1.63% from ¥1.23 in 2020[29]. - The company's R&D expenditure as a percentage of revenue increased to 5.25%, up from 3.59% in 2020, indicating a focus on innovation[29]. - The company reported a quarterly revenue of approximately ¥1.62 billion in Q4 2021, with a net profit of approximately ¥171.77 million for the same period[30]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 6.80 per 10 shares, totaling RMB 306 million, which represents 56.11% of the net profit attributable to shareholders for the year 2021[6]. Operational Risks and Governance - The company has detailed various operational risks and corresponding countermeasures in the report[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has not indicated any special arrangements for corporate governance[7]. - The company has not faced any violations in decision-making procedures for external guarantees[10]. - The company has not disclosed any significant risks beyond those already mentioned in the report[4]. - The company has not reported any instances where more than half of the directors could not guarantee the authenticity, accuracy, and completeness of the annual report[10]. Research and Development - The company is actively developing two new innovative drugs, with clinical trials expected to commence in Q3 2022[20]. - The company has allocated 200 million RMB for research and development in the upcoming year, focusing on enhancing drug efficacy and safety[20]. - The company has a total of 62 research projects, including 14 innovative drug projects and 39 generic drug projects under evaluation[43]. - The company applied for 54 new patents in 2021, including 29 invention patents, and has a total of 157 patents as of the end of the reporting period[43]. - The company is focusing on mRNA vaccines and small nucleic acid drugs, marking a significant shift in its R&D model since 2021, with a commitment to innovative drug transformation and development in key therapeutic areas such as cardiovascular diseases, tumors, and infectious diseases[59]. - The company has established eight core technology platforms, including those for nucleic acid drugs, small molecule innovation drugs, and controlled-release formulations, which are crucial for its revenue generation[138]. - The company has developed a universal technology platform for small nucleic acid and mRNA drug development, aiding in the discovery of new targets and the design of nucleic acid sequences for various vaccines and therapeutics[139]. - The company has established a robust process development and scale-up platform for nucleic acid drugs, meeting international quality standards for clinical trial products[139]. - The company is actively pursuing the industrialization of various new drugs, including nucleic acid therapies and pediatric-specific formulations, demonstrating its focus on expanding its product pipeline[145]. Market Expansion and Strategy - Youcare Pharmaceutical plans to enter three new international markets by the end of 2023, aiming to increase its global footprint[20]. - The company is implementing a new pricing strategy aimed at increasing market share while maintaining profitability[20]. - The company has established a partnership with a leading healthcare provider to enhance distribution channels and improve access to its products[20]. - The company aims to leverage its first-mover advantage and high-quality production standards to expand its market space[103]. - The company plans to continue expanding its market presence with new product launches and technological advancements[198]. Industry Trends and Outlook - The global pharmaceutical market is projected to grow to $2.1 trillion by 2030, with China being a major driver of growth in emerging markets[72]. - The healthcare expenditure in China is expected to continue rising, with total health spending projected to grow from over ¥8 trillion in 2020 to ¥16 trillion by 2030[73]. - The aging population in China is accelerating, with 264 million people aged 60 and above, accounting for 18.7% of the population, and 190 million aged 65 and above, making up 13.5%[74]. - The pharmaceutical industry is characterized by high innovation capability, significant investment density, and long investment return cycles, making it a strategic sector for national health and security[77]. - The ongoing medical reform and the "three medical linkages" policy are expected to drive the pharmaceutical industry towards high-quality development and increased market concentration[78]. - The focus on generic drug quality improvement and the dynamic adjustment mechanism of the medical insurance catalog will enhance drug accessibility and fairness in medication[79]. Challenges and Risks - The company faces risks related to new drug development, including lengthy approval processes that can take over ten years[176]. - There is a risk of core technology leakage and infringement, despite established protective measures[177]. - The company is at risk of losing key technical personnel, which could impact its competitive edge and innovation capabilities[178]. - Compliance risks exist that could affect the company's reputation and operational performance if not managed properly[180]. - The ongoing global economic downturn poses a risk to the company's operational performance and profitability, despite the relative resilience of the pharmaceutical industry[192]. - The company is exposed to raw material price fluctuations, which could negatively affect gross margins if prices remain high or increase further[184]. - The company has established a comprehensive quality assurance system, but there remains a risk of potential product quality issues that could adversely affect operations[185].

Financial Performance - The company's operating revenue for Q1 2022 was ¥900,836,570.89, representing a year-on-year increase of 2.48%[6] - The net profit attributable to shareholders was ¥63,467,735.64, showing a decline of 9.58% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥57,015,244.60, down 14.92% year-on-year[6] - The basic earnings per share were ¥0.14, reflecting a decrease of 12.50% year-on-year[6] - Total operating revenue for Q1 2022 was CNY 900,836,570.89, an increase of 2.0% compared to CNY 879,074,205.93 in Q1 2021[31] - Net profit for Q1 2022 was CNY 63,971,233.59, a decrease of 9.3% from CNY 70,276,993.94 in Q1 2021[35] - Basic earnings per share for Q1 2022 were CNY 0.14, down from CNY 0.16 in Q1 2021[37] Research and Development - The total R&D investment amounted to ¥107,500,189.55, an increase of 192.96% year-on-year, accounting for 11.93% of operating revenue, up 7.76 percentage points[9] - Research and development expenses increased significantly to CNY 73,938,790.33 in Q1 2022, compared to CNY 32,487,090.30 in Q1 2021, representing a growth of 128.2%[35] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥32,912,014.96, indicating a significant decrease compared to the previous year[6] - Cash flow from operating activities was CNY 1,056,790,930.07 in Q1 2022, compared to CNY 1,091,062,823.15 in Q1 2021, indicating a decrease of 3.1%[37] - Net cash flow from operating activities was -$32.91 million, a decrease from -$7.80 million in the previous period, indicating a worsening cash flow situation[40] - Total cash inflow from operating activities was approximately $1.10 billion, while cash outflow was about $1.13 billion, resulting in a net cash outflow of $32.91 million[40] - Cash flow from investing activities showed a net outflow of approximately $174.59 million, compared to a net outflow of $187.84 million in the previous period[40] - Cash flow from financing activities resulted in a net outflow of $9.09 million, an improvement from a net outflow of $97.80 million previously[42] - The ending balance of cash and cash equivalents was approximately $2.07 billion, down from $2.09 billion at the end of the previous period[42] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,657,588,561.47, a decrease of 1.21% from the end of the previous year[9] - The company's cash and cash equivalents decreased to RMB 2,191,886,310.36 from RMB 2,436,137,019.63 year-over-year[23] - Accounts receivable decreased to RMB 729,164,856.71 from RMB 816,812,146.63, indicating a reduction of approximately 10.7%[26] - Inventory increased to RMB 748,319,393.88 from RMB 632,314,542.55, reflecting an increase of about 18.4%[26] - Total current liabilities decreased to RMB 1,496,389,165.67 from RMB 1,682,202,891.72, a reduction of approximately 11.0%[29] - The company's non-current assets totaled RMB 1,827,827,856.04, up from RMB 1,660,976,354.24, indicating an increase of about 10.1%[29] - The total liabilities decreased to RMB 1,641,949,396.89 from RMB 1,799,673,767.06, a decrease of approximately 8.8%[29] - The company reported a significant increase in other non-current assets, rising to RMB 137,889,369.57 from RMB 67,811,422.55, an increase of about 103.5%[26] - The company's total current assets decreased to RMB 3,829,760,705.43 from RMB 4,065,814,783.54, a decrease of approximately 5.8%[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,594[15] - The company's total equity attributable to shareholders reached CNY 4,011,137,843.58, up from CNY 3,923,740,371.80 in the previous year[31] Expenses - Total operating costs for Q1 2022 were CNY 841,629,577.42, up from CNY 800,319,681.90 in Q1 2021, reflecting a year-over-year increase of 5.5%[31] - The company reported a decrease in sales expenses to CNY 378,294,755.36 in Q1 2022 from CNY 391,028,556.61 in Q1 2021, a reduction of 3.2%[35] - Cash paid to employees increased to $116.30 million from $87.61 million, reflecting a significant rise in labor costs[40] - Cash paid for taxes decreased slightly to $113.88 million from $118.39 million, indicating a reduction in tax liabilities[40] - Cash paid for purchasing goods and services was approximately $341.23 million, up from $338.92 million, showing stable operational expenses[40]